ALVOW Company Profile and Key Details

Dividend and splits history remains an important factor for investors monitoring long-term returns.

ALVOW has shown sold momentum, gaining 7.49% over the past week and 250.17% over the past quarter, though year-to-date performance is up 221.12%. Average 10-day trading volume of 806.00 shares is below the 3-month average of 3.54 thousand, indicating normal recent market interest.

Alvotech earnings surprise history is a mixed track record. The quarter that ended August 19, 2026, missed forecasts by 2.66%. The prior quarter beat by 91.49%. Over the last six quarters, Apple has recorded several small beats. These include -330.17% in August 13, 2025.

Alvotech (NASDAQ:ALVOW) shares are up 221.12% year-to-date Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Alvotech trading at a premium to the broader market with a P/E of -9.03.

Our AI price prediction model suggests that Alvotech stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 468.53%, with price expected at $1.68 by November 24, 2023, within a range of $1.48 to $1.90

The stock is currently trading near its 52-week low $0.30 and $1.52. With a market capitalization of about $2.74 billion, Alvotech is classified as a mid-cap and shows lower-than-market volatility (beta ~0.19). Key stats such as the average daily volume over the past year has been around 3.68 thousand shares, volume is running light vs its 52-week average. Headquartered in Luxembourg, LU, Alvotech operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Lisa Graver, the company employs approximately 1,460 people and listed since June 16, 2022. Alvotech Holdings SA is an Icelandic enterprise that, operating via its subsidiary companies, undertakes the development and fabrication of biosimilar pharmaceuticals destined for international consumption.

Alvotech trades at a P/E ratio of -9.03, slightly below the S&P 500 average, with a price-to-sales ratio of 3.63 and a price-to-book ratio of -9.83 indicating negative book value, which may reflect financial stress. The P/FCF stands at -5.94, also below market averages.